Da Lian Shi

Researchers are evaluating zorifertinib as a first-line treatment for patients with advanced non-small cell lung cancer NSCLC that has mutations in the EGFR gene and has spread to the central nervous system CNS. This prospective study involves multiple centers and compares the survival benefits and safety of zorifertinib to other similar drugs called EGFR tyrosine kinase inhibitors EGFR-TKIs. The study aims to better understand how well zorifertinib works and its clinical value in this patient group. Participants are divided into three groups those receiving first-line zorifertinib who meet criteria of the EVEREST study, those receiving zorifertinib but not meeting EVEREST criteria, and those receiving other anti-tumor drugs chosen by their doctors excluding zorifertinib. The EVEREST study is an open-label trial comparing zorifertinib to gefitinib or erlotinib. Treatments are given as prescribed by clinicians, with monitoring of safety and dosage adjustments as needed. During the study, participants will be followed for up to 36 months, with assessments every 8 weeks to measure overall survival, progression-free survival, intracranial progression, response rates, and adverse events. Researchers will track dose changes and monitor safety outcomes over time. The study collects clinical data to evaluate the effectiveness and tolerability of the treatments in patients with EGFR-mutant advanced NSCLC and CNS metastases.

Researchers are evaluating the efficacy and safety of a new drug called STN1013800 ophthalmic solution for treating acquired blepharoptosis in Chinese patients. This condition involves drooping of the upper eyelid, and currently, there are no approved medicines for this in China. This is a Phase III randomized, double-masked, placebo-controlled study designed to compare STN1013800 with a placebo solution. Participants will receive either 0.1% STN1013800 ophthalmic solution or a placebo once daily for 42 days, based on prior clinical trial results. The study includes a screening period lasting 3 to 7 days to confirm eligibility. The interventions involve applying the assigned eye drops daily, with the study treatment and placebo groups monitored in parallel. During the study, participants will undergo multiple assessments including margin reflex distance-1 MRD-1 measurements and Leicester Peripheral Field Test LPFT scores at several time points Day 1 Hour 6, Day 14 Hour 2, and Day 42. Researchers will track changes from baseline in eyelid position and visual function to evaluate treatment effects. Safety and adherence will also be monitored throughout the 42-day treatment period.

Researchers are studying TQC2731 injection, a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin TSLP to block its pathway and reduce inflammation. This clinical trial focuses on patients with chronic rhinosinusitis with nasal polyps CRSwNP to evaluate the safety and effectiveness of TQC2731 injection. Participants will receive either TQC2731 injection or a placebo in treatment cycles lasting 4 weeks. The study is randomized, double-blind, and placebo-controlled, with repeated treatment cycles. The effects on nasal polyp size and nasal congestion will be assessed over a 24-week period, with additional measures taken up to 60 weeks. During the trial, participants will undergo nasal endoscopy to score nasal polyps and congestion, complete symptom questionnaires, and have blood and nasal tissue samples collected at various points. Safety monitoring includes tracking adverse events and immune response tests. The study duration extends to 60 weeks to evaluate long-term outcomes and treatment impact.

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.